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Background: The aim of this study was to compare measures of exercise capacity, 
health-related quality of life (HRQoL), muscle force, lung function and feelings of 
anxiety and depression in people after curative intent treatment for NSCLC with age 
and gender-matched healthy controls. 
Methods: This cross-sectional study included 23 participants (68±10yr; 16 females), 6 
to 10 weeks after lobectomy for NSCLC or, for those who received adjuvant 
chemotherapy, 4 to 8 weeks after their last cycle. The study also included 20 age and 
gender-matched healthy controls (69±5yr; 13 females). All participants underwent 
measurements of exercise capacity (cycle-ergometry test [CPET] and six-minute walk 
test [6MWT]), HRQoL (Short-Form 36 general health survey [SF-36]), handgrip force, 
quadriceps torque, lung function and feelings of anxiety and depression.  
Results: When compared with data collected in healthy controls, those in the NSCLC 
group demonstrated impairments in the peak rate of oxygen consumption (15±3 versus 
24±7ml·kg-1·min-1; p<0.001) and maximum work rate (75±25 versus 127±51Watts; 
p<0.001) measured during the CPET, and 6-minute walk distance (494±77 versus 
649±61m; p<0.001). Similarly, impairments were demonstrated in all domains of the 
SF-36 (p<0.01 for all), isometric handgrip force (28±7 versus 34±10kg; p=0.02), and all 
measures of lung function (p≤0.001 for all). A higher score for depression was also seen 
(3.0±2.5 versus 1.5±1.6; p=0.03). There was no difference between the groups in 
isometric quadriceps torque or feelings of anxiety.   
Conclusions: After curative intent treatment for NSCLC, compared to healthy controls, 
impairments were demonstrated in laboratory and field-based measures of exercise 
capacity, HRQoL, isometric handgrip force and lung function. Although people after 
 
 
curative intent treatment for NSCLC reported greater feelings of depression, these levels 
were below those considered clinically relevant. These findings suggest that people after 
curative intent treatment for NSCLC may benefit from rehabilitative strategies to 
optimise exercise capacity and HRQoL. 
 






6MWD – Six-minute walk distance 
6MWT – Six-minute walk test 
CI – Confidence interval 
CPET – Cardiopulmonary exercise test 
HADS – Hospital Anxiety and Depression Scale 
HRQoL – Health-related quality of life 
LLN – Lower limit of normal 
MD – Mean difference 
MCS – Mental component score 
NSCLC – Non-small cell lung cancer 
PCS – Physical component score 
SF-36 – Medical outcomes study Short-Form 36 general health survey 
VO2peak - Peak rate of oxygen consumption 





For people diagnosed with early stage non-small cell lung cancer (NSCLC), lung 
resection, with or without adjuvant chemotherapy, is considered curative intent 
treatment [1]. Although lung resection is associated with post-operative pulmonary 
complications such as lung collapse, pneumonia and prolonged mechanical ventilation, 
people with lung cancer perceive the likelihood of a physical debility as more important 
and undesirable [2].  
There is a dearth of studies exploring the impact curative intent treatment has on 
functional outcomes. Earlier work that has attempted to quantify impairments in people 
after curative intent treatment for NSCLC has focused exclusively on measures of lung 
function, maximal exercise capacity and health-related quality of life (HRQoL) [3-6]. It 
is unknown whether people after curative intent treatment for NSCLC present with 
impairments in other measures that are likely to be important, such as six-minute walk 
distance (6MWD), peripheral muscle force, and feelings of anxiety and depression. 
Such data would allow healthcare professionals to provide their patients who have been 
diagnosed with early stage NSCLC with realistic information regarding the magnitude 
of impairments they may experience after curative intent treatment. It may also provide 
a target for rehabilitation strategies, such as exercise training. Further, although studies 
have demonstrated that lung function and maximal exercise capacity are expected to 
decrease after curative intent treatment for NSCLC [3-6], these data were published 10 
to 20 years ago, when the surgical techniques were considerably different to those used 
at present [7]. Data on impairments in lung function and exercise capacity that follow 
current surgical management and techniques are warranted.   
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The aim of this study was to compare measures of exercise capacity, HRQoL, 
peripheral muscle force, lung function and feelings of anxiety and depression made in 
people after curative intent treatment for NSCLC, with those made in age and gender-
matched healthy controls. The hypothesis was that, compared to age and gender-
matched healthy controls, all outcomes will be impaired in those who have completed 
curative intent treatment for NSCLC.  
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Materials and Methods 
See online supplement for more details on study exclusion criteria, recruitment, sample 
size calculation and measurements. 
Study design and participants 
This was a cross-sectional and observational study. People were included if they were 6 
to 10 weeks following lobectomy for NSCLC (stage I, II or IIIA) or, for those who 
required adjuvant chemotherapy following surgery, 4 to 8 weeks following their last 
cycle. Exclusion criteria comprised: presence of co-morbid conditions thought to 
compromise safety during the assessments such as uncontrolled hypertension; severe 
neuromusculoskeletal limitations; participation in exercise training in the last 3 months 
and; inability to understand spoken or written English. People with NSCLC were 
recruited from outpatient clinics and from referrals to the exercise training programmes 
at two tertiary hospitals in Perth. Regarding the healthy controls, Perth residents, with 
normal spirometry, aged between 55 and 80 years were eligible to participate. Exclusion 
criteria comprised the presence of any cardiac or neuromusculoskeletal condition 
thought to adversely influence performance during the assessments and the inability to 
understand spoken or written English. Stratified sampling was used to select healthy 
people who responded to the advertisements on the Curtin University radio station and 
in a community newspaper.  
Assessments were initiated after participants gave written informed consent and were 
undertaken over 2 or 3 days, over a period of 2 to 3 weeks. There was a minimum of 24 
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hours between assessment days. The study was approved by the Human Research Ethics 
Committees of two tertiary hospitals (approval numbers 2011/105 and RA-11/033) and 
Curtin University (HR 178/2011). 
Protocol and measurements 
For those with NSCLC (NSCLC group), the first two assessment days took place at the 
hospital at which they had received their treatment. The first two assessment days for 
the healthy controls took place at one of these hospitals. On the first assessment day, all 
participants performed two six-minute walk tests (6MWTs) [8-10], completed the 
medical outcomes study Short-Form 36 general health survey (SF-36) [11-13], the 
Hospital Anxiety and Depression Scale (HADS) [14] and had their isometric handgrip 
force measured [15]. On the second assessment day, all participants completed 
spirometry [16] and a symptom-limited ramp cycle-ergometry cardiopulmonary 
exercise test (CPET) [17]. The third assessment day took place at Curtin University, 
during which a measure was collected of isometric quadriceps muscle torque [18, 19]. 
As the university is approximately 15km from either of the hospitals, participants were 
given the option to decline this assessment. 
Statistical analyses 
Statistical analyses were performed using SPSS® (Statistical Package for Social 
Sciences, version 22.0). The distribution of data was examined by the Shapiro-Wilk test 
and all data were normally distributed. Between-group comparisons of continuous data 
were undertaken using independent-samples t-tests. Pearson Chi-square was used for 
comparison of categorical data. Differences between groups are reported as mean 
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difference (MD) and 95% confidence interval (CI). For measures of function (e.g. 
exercise capacity and peripheral muscle force) that demonstrated a significant difference 
between the groups,  data from the healthy controls were used to calculate the lower 
limit of normal (LLN). The LLN was defined as the 5th percentile, that is, the value 
above which 95% of the measures obtained in the healthy control group were situated 
[20, 21]. For the NSCLC group, exploratory subgroup analyses were undertaken using 
independent t-tests to compare outcome measures between (i) in people with vs. without 
chronic obstructive pulmonary disease COPD [22] and (ii) people who underwent video 
assisted thoracoscopic surgery (VATS) vs. people who underwent open thoracotomy. 
For all analyses, a p value ≤0.05 was considered significant. All data are expressed as 
meanstandard deviation unless otherwise stated. 
Using published data on people with COPD [23], a sample size of 18 participants with 
NSCLC and 18 healthy controls was needed to detect a between-group difference in 
peak rate of oxygen consumption (VO2peak) of 0.55L·min





Twenty-three participants in the NSCLC group and 20 healthy controls were included in 
final analysis (Figure 1). Baseline characteristics of the two groups are presented in 
Table 1. The average time between lobectomy and the first day of assessment was 
54±17 days. Two participants received adjuvant chemotherapy. For these, the time 
between the last cycle of adjuvant chemotherapy and first day of assessment was 28 and 
55 days. The average time between the first and second day of assessment and between 





Figure 1: Study flow diagram 
Abbreviations: 6MWT – Six-minute walk test; CPET – Cardiopulmonary exercise test; HRQoL 




















































Abbreviations: BMI – Body-mass index; COPD – Chronic obstructive pulmonary disease; DLCO – 
Diffusing capacity for carbon monoxide; FEV1 – Forced expiratory volume in one second; FVC – Forced 
vital capacity; GORD - Gastro-oesophageal reflux disease; MVV – Maximum voluntary ventilation; 
NSCLC – Non-small cell lung cancer; SD – Standard deviation; TLC – Total lung capacity; VATS – 
Video-assisted thoracoscopic surgery. *Measures only collected in the NSCLC group.
Variable NSCLC Group (n=23) Healthy Controls (n=20) 
Age (yr) 
n % n % 

















Other cancers (treated) 
Stable heart disease 
Type of NSCLC  
Adenocarcinoma 
Squamous cell carcinoma 
Large cell carcinoma 
7/16 30/70 7/13 35/65 
1 5 0 0 
18 78 2 10 
4 17 18 90 
12 52 0 0 
13 57 2 10 
4 17 1 5 
4 17 1 5 
5 22 6 30 
3 13 1 5 
3 13 4 20 





39 ± 28 0.3 ± 0.9 < 0.001 
FEV
1
 (L)  1.65 ± 0.48 2.68 ± 0.54 < 0.001 
BMI (kg·m-2) 26 ± 6 25 ± 4 0.756 













Adjuvant chemotherapy 2 9 
FEV
1
 (%pred)   67 ± 16 103 ± 15 < 0.001 
FVC (L)  2.67 ± 0.71 3.44 ± 0.75 < 0.001 
FVC (%pred)   81 ± 11 99 ± 15 < 0.001 
Height (cm)  164 ± 12 167 ± 6 < 0.001 












MVV (L·min)  63 ± 23 78 ± 6 < 0.001 
MVV (%pred)   66 ± 19 119 ± 16 < 0.001 
D
L
CO (ml·mmHg-1·min-1)* 2.67 ± 0.71 
D
L
CO (%pred)*   81 ± 11 
TLC (L)*  4.65 ± 1.34 
TLC (%pred)*   84 ± 15 
FEV
1




Cardiopulmonary exercise test 
Compared with healthy controls, participants in the NSCLC group demonstrated a 
lower VO2peak, maximum work rate (Wmax), nadir arterial oxygen saturation (SpO2), 
peak heart rate, breathing reserve, oxygen pulse, and reported greater dyspnoea on test 
completion (Table 2). The LLN for the VO2peak and Wmax were 1.17L·min
-1 and 77W, 
respectively. Fifteen and ten of the 21 participants (71% and 48%) in the NSCLC group 
had a VO2peak or a Wmax, respectively, below the LLN.  
Six-minute walk test 
Compared with healthy controls, participants in the NSCLC group demonstrated a 
lower 6MWD, nadir SpO2, peak heart rate and reported greater dyspnoea and leg fatigue 
on test completion (Table 2). The LLN calculated for the 6MWD was 496m. Ten of 22 
participants (45%) in the NSCLC group had a 6MWD below the LLN. 
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Table 2: Measures obtained during the cardiopulmonary exercise test, six-minute walk test and 













































Abbreviations: 6MWT – Six-minute walk test; AT – Anaerobic threshold as a percentage of the VO2peak; BORGd – 
Dyspnoea; BORGf – Fatigue; BR – Breathing reserve; CI – Confidence interval; CPET – Cardiopulmonary exercise 
test; HR – Heart rate; HRmax – Maximal heart rate; O2 pulse – Oxygen pulse; RER – Respiratory exchange ratio; 
SD – Standard deviation; SpO2 - Arterial oxygen saturation measured via pulse oximetry; VEmax/MVV – 
Maximum minute ventilation, maximum voluntary ventilation ratio; VO2peak – Peak rate of oxygen consumption; 
Wmax – Maximum work rate. 












15 ± 3 24 ± 7 < 0.001 
64 ± 15 95 ± 23 < 0.001 
74 ± 20 122 ± 41 < 0.001 
mean ± SD mean ± SD 
75 ± 25 127 ± 51 < 0.001 
Mean difference (MD) 
-8.7 [-12.1 to -5.3] 
-32 [-44 to -19] 
-48 [-69 to -28] 
MD [95% CI] 
-52 [-77 to -26] 
BORGd
 
on completion CPET 
BORGf
 





6.9 ± 2.5 4.6 ± 1.8 0.002 
6.9 ± 2.4 6.3 ± 2.2 0.443 
129 ± 18 149 ± 12 < 0.001 
94 ± 4 96 ± 2 0.013 
2.3 [0.9 to 3.6] 
0.6 [-0.9 to 2.0] 
-20 [-29 to -10] 
-3 [-5 to -1] 
BR (%) 31 ± 16 48 ± 12 < 0.001 -17 [-26 to -8]  
6MWD (m) 
6MWD (%pred) 80 ± 11 104 ± 7 < 0.001 
494 ± 77 649 ± 61 < 0.001 
-24 [-29 to -18] 
-155 [-199 to -111] 
BORGd
 
on completion 6MWT 
BORGf
 




Peak HR (bpm) 
3.2 ± 1.6 1.4 ± 0.9 < 0.001 
2.0 ± 1.9 0.9 ± 0.9 0.025 
119 ± 14 137 ± 13 < 0.001 
93 ± 3 96 ± 1 < 0.001 
1.7 [0.9 to 2.6] 
1.1 [0.1 to 2.0] 
-18 [-27 to -10] 
-3 [-5 to -2] 
n = 21 
n = 22 
n = 20 
n = 20 
VO
2peak 
(L·min-1) 1.03 ± 0.31 1.69 ± 0.63 < 0.001 -0.65 [-0.96 to -0.34] 
O
2
 pulse (ml·beat-1) 8 ± 3 11 ± 4 0.004 -3 [-5 to -1]  
AT (%VO2peak) 62 ± 9 60 ± 6 0.601 -1.3 [-3.7 to -6.3]  
VEmax/MVV (%) 69 ± 16 51 ± 12 < 0.001 18 [9 to 27]  
Isometric handgrip force 
Handgrip (kg) 
Handgrip (%pred) 101 ± 21 123 ± 21  0.001 
28 ± 7 34 ± 10  0.023 
-21 [-35 to -9] 
-6 [-11 to -1] 
Quadriceps (Nm) 
Quadriceps (%pred) 
127 ± 64 120 ± 40  0.710 
97 ± 19 104 ± 17 0.381 
8 [-35 to 50] 
-6 [-21 to 8] 
n = 22 n = 20 
Isometric quadriceps torque n = 12 n = 14 
RER  1.22 ± 0.10 1.32 ± 0.18 0.032 0.10 [0.02 to 0.17]  
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Isometric handgrip force and isometric quadriceps torque  
Compared with healthy controls, participants in the NSCLC group demonstrated a 
lower isometric handgrip force (Table 2). The LLN calculated for this outcome measure 
was 22kg. Five of 22 participants (23%) in the NSCLC group had isometric handgrip 
force below the LLN.  
No between-group difference was demonstrated in isometric quadriceps torque (Table 
2). 
Health-related quality of life and feelings of anxiety and depression 
Compared with healthy controls, participants in the NSCLC group demonstrated a 
lower physical component score (PCS) and mental component score (MCS) (Table 3). 
Lower scores were also demonstrated for each of the eight domains assessed using the 
SF-36 (Table 3).  
Pertaining to the HADS, participants in the NSCLC group reported greater score for 
depression. Nevertheless, mean scores for both anxiety and depression components of 
the HADS of participants in the NSCLC and healthy control groups were below the 
































Abbreviations: CI – Confidence interval; HADS – Hospital anxiety and depression scale; MCS – Mental component score; NSCLC – Non-small cell 
lung cancer; PCS – Physical component score; SD – Standard deviation; SF-36 – Medical outcomes study Short-Form 36 general health survey.
Variable NSCLC Group 
(n=22) 







45 ± 5 56 ± 5 < 0.001 
51 ± 8 57 ± 7 0.008 
60 ± 22 94 ± 9 < 0.001 
mean ± SD mean ± SD 
62 ± 19 93 ± 8 < 0.001 
Mean difference   
(MD) 
-11 [-15 to -8] 
-6 [-11 to -2] 
-34 [-45 to -23] 
MD [95% CI] 





62 ± 19 81 ± 15 0.001 
67 ± 18 91 ± 9 < 0.001 
76 ± 21 94 ± 12 < 0.001 
60 ± 18 77 ± 13 0.001 
-19 [-29 to -8] 
-24 [-33 to -15] 
-19 [-30 to -8] 
-17 [-27 to -7] 
Role emotional 73 ± 23 95 ± 12 < 0.001 -22 [-33 to -10] 
Mental health 75 ± 16 89 ± 12 0.003 -14 [-22 to -5] 
SF-36 
HADS 
Anxiety score 4.1 ± 2.4 2.9 ± 2.5  0.112 1.2 [-0.3 to 2.8] 
Depression score 3.0 ± 2.5 1.5 ± 1.6 0.026 1.5 [0.2 to 2.9] 
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Lung function  
Compared with healthy controls, participants in the NSCLC group demonstrated 
impairments in all measures of lung function (Table 1).  
Exploratory subgroup analysis  






This study has demonstrated that, compared to age and gender-matched healthy 
controls, people after curative intent treatment for NSCLC have impaired exercise 
capacity, HRQoL, isometric handgrip force and lung function. Isometric quadriceps 
torque appears to be preserved; however, only a subgroup of participants attended this 
assessment. Although those in the NSCLC group reported greater feelings of 
depression, the mean score for depression in this group was low. 
Earlier work that has measured the exercise capacity of people after curative intent 
treatment for NSCLC reported similar VO2peak, Wmax and 6MWD as the current study 
[4, 24]. The novel finding of this study is that after curative intent treatment for 
NSCLC, more than two-thirds (71%) of participants had a VO2peak below the LLN 
established in healthy controls and almost half achieved a Wmax and 6MWD that were 
below the LLN. These data suggest that people after curative intent treatment for 
NSCLC are more likely to present with impairment in maximal exercise capacity (i.e. 
VO2peak) than in functional exercise capacity (i.e. 6MWD). It is also possible that the 
smaller between-group difference in 6MWD, compared to measures of exercise 
capacity obtained during the CPET, reflected the fact that those in the healthy control 
group were limited from walking further during the 6MWT by mechanical factors such 
as stride length. This so-called ceiling effect on 6MWD in the healthy control group 
may have reduced our estimation of differences in 6MWD between the two groups. Of 
note, the VO2peak of 15±3ml·kg·
-1·min-1 (or 64±15%pred) shown in this study is similar 
to the VO2peak reported in people with moderate-to-severe COPD [25, 26] in whom 
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exercise training has been shown to improve exercise capacity [25]. Although exercise 
training has been established as a treatment option in people with COPD, referral of 
people following lung resection for lung cancer to exercise training programmes is low 
[27]. The impairment in VO2peak demonstrated in this study combined with previous 
work that has shown that VO2peak is an independent predictor of mortality in people with 
NSCLC [28], supports the need for rehabilitative strategies to optimise exercise 
capacity in this population.  
Compared to healthy controls, both the PCS and the MCS of the SF-36 were decreased 
in participants in the NSCLC group. Of note, the magnitude of the mean difference in 
the PCS between the two groups -11[-15 to -8]) was almost twice that seen in the MCS 
(-6[-11 to -2]). This suggests that people after curative intent treatment for NSCLC 
perceive their HRQoL to be more affected by physical problems than by mental or 
emotional problems. This contention is supported by earlier work which has 
demonstrated a worsening of 14 to 19% in the physical components of HRQoL up to 6 
months following lung resection for NSCLC [6, 29, 30], whereas the mental 
components of HRQoL have been shown to have minimal, if any, change [31-33]. Of 
note, compared to the Australian population norms [34] (PCS: 50 [50 to 51]; MCS: 53 
[52 to 53]), the mean PCS score of the NSCLC group (45±5) was 5 points lower, 
whereas the mean MCS score (51±8) was only 2 points lower. Minimal impairment in 
the mental health of the NSCLC group is in keeping with our data showing that feelings 
of anxiety and depression were within normal ranges (HADS anxiety and depression 
scores ≤7) in the NSCLC group. 
16 
 
Scores for feelings of anxiety were also reported by Granger et al [35], who followed 50 
participants with stage IA to IIIB NSCLC from the time of diagnosis to 6 months 
following diagnosis. Half of the participants (25 of 50) underwent lung resection (with 
or without adjuvant chemotherapy) and the remaining 25 participants received 
chemotherapy, radiotherapy or a combination of both. The study demonstrated no 
change in anxiety scores from diagnosis to 6 months (5.5±0.7 versus 5.5±0.7; p=0.94) 
[35]. Subgroup analysis comparing changes in the anxiety score of participants who 
underwent lung resection and those who did not undergo lung resection were not 
performed, precluding the comparison with findings from the present study. 
This is the first study to demonstrate impairment in isometric handgrip force in people 
after curative intent treatment for stage I, II or IIIA NSCLC. Participants in the NSCLC 
group were 17% weaker than healthy controls (28±7 versus 34±10kg; p=0.02). The 
relevance of this finding is that handgrip force is related to general muscle strength in 
older adults [36] and it is also a prognostic factor for mortality in middle-aged and older 
people [37]. Although the changes in peripheral muscle force after curative intent 
treatment for NSCLC needs further investigation, the measurement of handgrip force 
may assist in identifying those who present with impairments in general muscle 
strength.  
Given the impairments in handgrip force, it is somewhat surprising that measures of 
quadriceps torque were similar between the NSCLC and healthy control groups. 
However, a previous study of 13 people with thoracic cancers and 13 matched healthy 
controls has also reported similar quadriceps muscle torque in both groups (median 
[interquartile range] 65 [27 to 71] versus 74 [54 to 84]Nm, respectively; p>0.05) [19].  
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It also appears that quadriceps force recovers to pre-operative measures within 3 months 
of surgery. Arbane et al [38] investigated quadriceps twitch force via magnetic 
stimulation of the femoral nerve in 25 people undergoing lung resection for NSCLC. 
They demonstrated no change in measures collected 12 weeks following lung resection 
compared to those collected pre-operatively. However, of the 25 people with NSCLC 
who were assessed prior to lung resection in that study, only 13 (52%) returned for the 
12-week assessment [38]. This was a substantial attrition rate (48%) and it is possible 
that those people who returned for the 12-week assessment were not representative of 
the total sample. This is also likely to have occurred in the current study. That is, only 
12 of the 23 participants (52%) in the NSCLC group underwent measurement of 
isometric quadriceps muscle force. Therefore, although further study is needed to 
determine changes in quadriceps force after curative intent treatment for NSCLC, our 
data demonstrating reduced hand grip force suggests that peripheral muscle strength is 
impaired in this group. 
Not surprisingly, compared to healthy controls, all variables of lung function were 
decreased in the NSCLC group. Lung function has consistently been shown to decrease 
after lung resection for NSCLC [39, 40] and our results corroborate results from these 
previous studies.  
Study strengths and limitations 
Compared to previous studies that assessed outcomes in people after lung resection for 
NSCLC, this study was the first to include a broad range of outcomes measures and 
compare them with data collected in age and gender-matched healthy controls. The 
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current study demonstrated that patients were able to tolerate this comprehensive 
assessment protocol at this time. This increases the rationale to consider referring these 
patients for rehabilitation as soon as 6 weeks following surgery. This study was also the 
first to assess exercise capacity of people following lung resection for NSCLC using 
both a laboratory-based (CPET) and a field-based exercise test (6MWT). The optimal 
study design to quantify the impact of curative intent treatment for NSCLC on measures 
such as exercise capacity, HRQoL, peripheral muscle force, lung function and feelings 
of anxiety and depression would be to collect measures prior to and after treatment in 
the same sample. Nevertheless, such a design was not possible at our hospitals as the 
time between the decision to operate and the date of surgery was often less than one 
week and patients were unable to accommodate the additional visits required for the 
study assessments. Comparing measures obtained in people after curative intent 
treatment for NSCLC with those collected in healthy controls, did not delay surgery and 
was the only feasible study design to quantify impairment in this patient group. Further, 
rather than use reference equations to estimate measures in a healthy population, 
comparing measures between those after curative intent treatment for NSCLC with 
those that have been collected in healthy controls in the same laboratory, by the same 
investigator, ensures that between-group differences were not due to disparities in 
testing protocols and equipment. 
The main limitation of this study relates to the limited number of healthy controls 
available to calculate the LLNs. These calculations may have been more robust if a 
larger sample were available. Nevertheless, in an earlier study which reported 
impairments in participants with cystic fibrosis the same number of healthy controls 
were used to derive measures of LLN [21]. Another limitation of the current study was 
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that people who underwent wedge resection or pneumonectomy for NSCLC were not 
included, thus our findings cannot be extended to all people undergoing curative intent 
treatment for NSCLC. Further, although there was no significant difference in the 
percentage of people in both groups with diabetes mellitus (DM), the NSCLC had three 
times as much people with DM than the healthy controls group, and this may have 
contributed to their impairment in exercise capacity. Another limitation of the study was 
that, although the two groups were balanced for age and gender, we did not seek to 
balance the groups in terms of participation in daily physical activity. It is possible that 
the healthy controls participated in greater physical activity and that this factor 
contributed to the magnitude of between-group difference in maximum exercise 
capacity. Finally, this study includes a large number of between-group comparisons 
which increases the risk of type I error. Nevertheless, as the between-group differences 
for measures of exercise capacity, HRQoL and lung function were large and resulted in 




The greatest impairment detected in people after curative intent treatment for NSCLC, 
compared to healthy controls, was in exercise capacity. The magnitude of difference 
between groups in variables of exercise was large and 71% of participants after curative 
intent treatment for NSCLC presented decreased maximal exercise capacity (i.e. VO2peak 
below the LLN). Compared to age and gender-matched healthy controls, people after 
curative intent treatment for NSCLC also demonstrated impairments in HRQoL, 
isometric handgrip force and lung function. Conversely, quadriceps torque and feelings 
of anxiety were similar to that measured in age and gender-matched healthy controls. 
Although in those after curative intent treatment for NSCLC greater feelings of 
depression were reported compared to healthy controls, these levels were below those 
considered clinically relevant. 
These findings provide important information to clinicians working in the field. They 
highlight impairments in some patient-centred outcomes after curative intent treatment 
for NSCLC. They also allow health professionals to provide their patients with realistic 
information regarding the magnitude of these impairments. Further studies are 
necessary to demonstrate whether impairments exist prior to curative intent treatment 
and whether rehabilitation strategies are of benefit to improve exercise capacity and 
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Impairments after curative intent treatment for non-small cell lung cancer: 
a comparison with age and gender-matched healthy controls 
 
Short title: Outcomes following curative intent treatment for non-small cell lung cancer 




1. Study design and participants 
1.1 Study exclusion criteria 
Exclusion criteria of people following curative intent treatment for non-small cell lung cancer 
(NSCLC) comprised: presence of co-morbid conditions thought to compromise safety during 
the assessments such as uncontrolled hypertension; severe neuromusculoskeletal limitations; 
participation in exercise training in the last 3 months and; inability to understand spoken or 
written English. The rationale for excluding people who had participated in exercise training 
in the last 3 months was because exercise training has been demonstrated to improve exercise 
capacity in this population [1] and this would reduce the difference between groups. 
1.2 Recruitment 
A convenience sample of healthy controls was recruited using stratified sampling.  
Specifically, once we recruited the first 20 participants in the NSCLC group, we calculated 
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the mean age and proportion of males vs females. Thereafter, in order to ensure that the 
healthy control group were similar to the NSCLC, strata were created for age and gender 
proportion based on the sample characteristics of the NSCLC group. These strata were (i) 4 
people aged 55 to 60 yr; 0 males and 4 females (ii) 7 people aged 61 to 70 yr; 3 males and 4 
females and (iii) 9 people aged 71 to 80 yr; 4 males and 5 females. Subsequently, 20 healthy 
controls were recruited into these strata in the order to which they responded to the 
advertisements. This process was suggested by a statistician in order to ensure that 
participants in both group were ‘balanced’ in terms of age and gender proportion.  
In order to prevent selection bias of highly active healthy controls, the specific questions of 
both the advertisement and the radio text were: Are you aged between 55 and 80 years? Are 
you in good health? Are you a non-smoker? Can you spare some time to do a few tests at Sir 
Charles Gairdner Hospital? If you have answered “yes” to all these questions, please contact 
us for more information. 
2. Measurements  
2.1 Exercise capacity 
2.1.1 Cardiopulmonary exercise test (CPET) 
A symptom-limited ramp cycle ergometry exercise test was performed on an electronically 
braked bicycle ergometer (ER 900; Jaeger, Germany) in accordance with published 
guidelines [2]. Work rate increments during the test were determined using a published 
equation [3]. Increments varied from 1W every 12 seconds (i.e. 5W per minute) to 1W every 
5 seconds (i.e. 12W per minute). The increments in work rate were based on the participants 
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predicted maximum work rate (Wmax) [4] and chosen based on a 10-minute test duration [2, 
3, 5]. 
Participants rested on the bike for 3 minutes. They then cycled (between 50-60rpm) without 
any resistance for another 3 minutes. After this time, the resistance on the bike progressively 
increased until symptom limitation. Breath-by-breath measurements were collected 
(Medgraphics CardiO2; Medical Graphics Corporation, USA). Blood pressure was measured 
every 2 minutes by automated sphygmomanometry. Twelve-lead electrocardiography was 
used and arterial oxygen saturation measured via pulse oximetry (SpO2) was continuously 
monitored (Radical; Masimo Corporation, USA). The modified BORG scale (0-10) [6] was 
used to quantify level of dyspnoea (BORGd) and leg fatigue (BORGf) prior to starting the 
test, each minute during the test, and on test completion.  
Measures of the peak rate of oxygen consumption (VO2peak) and maximum minute ventilation 
(VEmax) collected during the CPET were averaged over the last 20 seconds of the test [2, 7, 
8]. The Wmax and measures of VO2peak were expressed in absolute values and as a percentage 
of the predicted value in a healthy population [4].  
2.1.2 Six-minute walk test (6MWT) 
The 6MWT was undertaken according to a protocol based on the American Thoracic Society 
recommendations [9]. It was performed over a 45-m straight course within an enclosed 
corridor. Standardised encouragement was given at the end of every minute. Also, at the end 
of every minute, measures were collected of heart rate (HR) (Polar a1; Polar Electro Oy, 




Two tests, separated by a 30-minute rest period, were conducted and the best six-minute walk 
distance (6MWD) achieved was recorded as the test result. The modified BORG scale [6] 
was used to quantify level of dyspnoea and leg fatigue prior to starting the test and on test 
completion. The 6MWD was expressed in absolute values and as a percentage of the 
predicted value in a healthy population [10]. 
2.2 Health-related quality of life (HRQoL) 
The medical outcomes study Short Form 36 general health survey (SF-36) was used to assess 
HRQoL. It comprises two major components: physical (physical component score [PCS]) and 
mental (mental component score [MCS]). The responses to items in each component are 
weighted equally, summed, and transformed to a 0 to 100 scale. Higher scores represent 
better HRQoL. The SF-36 has been widely used and its reliability and validity has been 
documented in people with a range of conditions that includes hypertension, diabetes, chronic 
heart failure and chronic obstructive pulmonary disease (COPD) [11-13]. 
2.3 Peripheral muscle force  
Maximal isometric torque of the quadriceps was measured in an upright seated position using 
the HUMAC NORM isokinetic dynamometer (CSMi; Stoughton, USA). The dominant leg 
(i.e. the leg they would kick a soccer ball) was chosen and participants were asked to perform 
five maximum contractions of the quadriceps at 60º of knee flexion. Each contraction was 
separated by 60 seconds. The contraction that generated the highest torque, and was within 
5% of another effort, was recorded as the test result. Measures were expressed in absolute 
values and as a percentage of the predicted value in a healthy population [14]. The equipment 
was calibrated prior to every test in accordance with the manufacturer’s recommendations.  
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Isometric handgrip force was measured using a hydraulic hand dynamometer (Jamar 
dynamometer; JA Preston Corporation; Jackson, MI, USA). Peak handgrip force was 
assessed bilaterally, with the elbow at 90° of flexion and the forearm and wrist in a neutral 
position. Measures were expressed in absolute values and as a percentage of the predicted 
value in a healthy population [15]. The hand dynamometer was calibrated at time intervals in 
accordance with the manufacturer’s recommendations. 
2.4 Lung function  
Lung function testing comprised measures made using spirometry (forced vital capacity 
[FVC] and slow vital capacity [SVC] manoeuvres), body plethysmography and diffusing 
capacity for carbon monoxide. The healthy controls only underwent the FVC manoeuvre and 
the maximum voluntary ventilation (MVV) assessment. Inhaled bronchodilator was not 
administered prior to lung function testing. The Medgraphics Elite Series DX 
plethysmograph (Medical Graphics Corporation, St Paul, MN, USA) was used to assess lung 
function and the equipment was calibrated prior to every test in accordance with the 
manufacturer’s recommendations. All the assessments were performed according to 
published guidelines on standardisation of lung function testing [16-19]. Measurements were 
expressed in absolute values and, where possible, as a percentage of the predicted value in a 
healthy population [20-22].   
2.5 Feelings of anxiety and depression  
Feelings of anxiety and depression measured using the Hospital Anxiety and Depression 
Scale (HADS) [23]. The HADS has been used to measure depression and generalised anxiety 
among hospitalised people, people attending outpatient clinics as well as in community 
settings [24-26]. It comprises 14 statements describing symptoms of depression (7 items) and 
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anxiety (7 items). Response options for each question range from 0 to 3, with a total range 
score between 0 and 21 for the depression and anxiety subscales. Higher scores represent 
greater feelings of depression and/or anxiety. Scores ≤ 7 are considered normal, scores > 7 
and < 11 are considered borderline abnormal and scores ≥ 11 are suggestive of a likely 
clinical diagnosis of depression or anxiety [23]. 
3. Statistical analyses 
3.1 Sample size calculation 
Compared with healthy controls, a previous study demonstrated that people with mild COPD 
had an average reduction in VO2peak of 0.36L·min
-1 [27]. Although many people with non-
NSCLC are likely to also have COPD, there will be a greater difference between the two 
groups in this study as the systemic effects of cancer as well as its treatment will increase the 
impairments in exercise capacity over and above those attributed to COPD. Therefore, we 
increased the magnitude of the between-group difference in VO2peak (i.e. 0.36L·min
-1 between 
people with mild COPD and healthy controls) by approximately 50%. That is, we estimated 
the magnitude of between-group difference in this study to be 0.55L·min-1. The decision to 
inflate the magnitude of the difference by 50% was arbitrary, but in the absence of any 
published literature to guide this calculation, this was considered a pragmatic approach. To 
estimate the standard deviation of the change for our sample size calculation, we averaged the 
standard deviation in the measurement of VO2peak previously reported in people with mild 
COPD and healthy controls (i.e. [0.55+0.59L·min-1] / 2 = 0.57L·min-1). Using these 
estimates, a sample size of 18 participants with NSCLC and 18 healthy controls were needed 
to detect a between-group difference in VO2peak of 0.55L·min
-1 with a standard deviation of 




Ninety-six people following curative intent treatment for NSCLC were screened to 
participate in this study, of whom 71% (n=68) were eligible and approached. Of these 68 
people, a total of 25 consented to participate (consent rate of 37%). The reasons for declining 
participation are outlined in Error! Reference source not found.. Two of the 25 (8%) were 
withdrawn due to health issues not related to lung cancer. Specifically, one participant was 
diagnosed with a primary bowel cancer and the other participant chose not to disclose the 
nature of the health issue that led to his withdrawal (Error! Reference source not found.). 
During the same time period, 32 healthy people expressed interest in the study after hearing 
the advertisement on the University radio station. Stratified sampling (strata of age and 
gender) was used to select the first 20 eligible healthy people who expressed an interest in 
participating, and those 20 people were included in the study. Twenty-three participants 
following curative intent treatment for NSCLC (NSCLC group) and 20 healthy controls were 
included in final analysis (Error! Reference source not found.). Baseline characteristics of 
the two groups are presented in Error! Reference source not found.. 
The average time between lobectomy and the first day of assessment was 54±17 days. Two 
participants (9%) received adjuvant chemotherapy. For these participants, the time lapse 
between the last cycle of adjuvant chemotherapy and first day of assessment was 28 and 55 
days.  
4.1 Exercise capacity 
4.1.1 Cardiopulmonary exercise test 
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All CPETs results were reviewed by a doctor who interpreted them to be a maximal effort 
test. The average duration of the CPET in the NSCLC group (9±2 minutes) was similar to 
that in healthy controls (10±2 minutes) (p=0.19). The average work rate increment during the 
CPET was smaller for the NSCLC group than for the healthy controls (8±2 versus 
13±4W/min; p<0.001). The VO2peak of the healthy controls ranged from 1.17 to 2.43 L·min
-1 
and their Wmax ranged from 77 to 301W.  The VO2peak of participants in the NSCLC group 
ranged from 0.56 to 1.48 L·min-1 and their Wmax ranged from 37 to 114W. The average 
VEmax of the participants in the NSCLC group was lower than the healthy controls 
(42.1±14.3 versus 61.1±20.1L/min; p=0.001). 
The number of participants who reached the American Thoracic Society/American College of 
Chest Physicians (ATS/ACCP) criteria for a  maximal effort test (i.e. achieved predicted 
VO2peak, predicted Wmax, predicted HRmax, VEmax/MVV ≥ 0.85 or respiratory exchange 
ratio [RER] ≥ 1.15) [2] are presented in Table A1. 
Regarding the symptoms that limited performance during the CPET, in the NSCLC group, 
eight participants (38%) were limited by dyspnoea, six (29%) were limited by leg fatigue, and 
seven (33%) were limited by a combination of dyspnoea and leg fatigue. For the healthy 
controls, four participants (20%) were limited by dyspnoea, 14 (70%) were limited by leg 
fatigue and two (10%) were limited by a combination of dyspnoea and leg fatigue. 
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Table A1:  Number of participants who reached the ATS/ACCP criteria of maximal effort 
ATS/ACCP criteria for a               
maximal effort test 
NSCLC Group 
(n=21) 
Helthy Controls  
(n=20)  
Predicted VO2peak 0 (0%) 6 (30%) 
Predicted Wmax 2 (10%) 13 (65%) 
Predicted HRmax 3 (14%) 10 (50%) 
VEmax/MVV ≥ 0.85 4 (19%) 0 (0%) 
RER ≥ 1.15 19 (90%) 20 (100%) 
 
Abbreviations: ATS/ACCP – American Thoracic Society/American College of Chest Physicians; HRmax – 
Maximal heart rate; RER – Respiratory exchange ratio; VEmax/MVV – Maximum minute ventilation, 




4.1.2 Six-minute walk test 
A comparison of variables collected during the 6MWT between the groups is presented in 
Error! Reference source not found.. Significant differences were observed in 6MWD, nadir 
SpO2, peak HR as well as dyspnoea and leg fatigue measured on test completion. The 6MWD 
of the healthy controls ranged from 493 to 730m. The 6MWD of participants in the NSCLC 
group ranged from 335 to 635m. 
4.2 Isometric quadriceps torque and isometric handgrip force 
Only 12 of 23 (52%) participants in the NSCLC group and 14 of 20 (70%) healthy controls 
attended Curtin University to undergo the measurement of isometric quadriceps torque (Table 
2). No between-group difference was demonstrated in isometric quadriceps torque (Table 2). 
The isometric handgrip force of the healthy controls ranged from 20 to 57kg. The isometric 
handgrip force of participants in the NSCLC group ranged from 18 to 45kg. 
4.3 Health-related quality of life and feelings of anxiety and depression 
The SF-36 demonstated that the mean difference (MD) [95% confidence interval (CI)] 
between the groups was greater in the PCS (-11[-15 to -8]) than in the MCS (-6[-11 to -2]) 
(p=0.001) (Table 3).  
Regarding the HADS, only one participant in the NSCLC group had a score >7 for anxiety 
and the same participant also had a score >7 for depression. Two healthy controls had a score 
>7 for anxiety, however feelings of depression were all within normal limits (i.e. ≤7). 
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4.4 Lung function  
Comparisons of lung function variables between the two groups are presented in Table 1. 
Significant differences were observed in all lung function variables.  
4.5 Relationships between exercise capacity and isometric quadriceps torque 
Isometric quadriceps torque correlated with both Wmax and VO2peak achieved during the 
CPET (r=0.84 and 0.81; respectively; p=0.001 for both). No correlation was found between 
isometric quadriceps torque and 6MWD (r=0.29; p=0.36).  
 
 
4.6 Subgroup analyses of people with COPD versus without COPD 
Of the 12 participants diagnosed with COPD, seven (58%) were females and five (42%) were 
males. Four (33%) had mild airway obstruction (i.e. GOLD stage 1), seven (58%) had 
moderate airway obstruction (i.e. GOLD stage 2) and one (9%) had severe airway obstruction 
(i.e. GOLD stage 3) following curative intent treatment for NSCLC. People with COPD had 
lower FEV1/FVC. No differences were found in any other outcome measures between the 
subgroup of people with COPD and the subgroup of people not diagnosed with COPD (Table 
A2). 
4.7 Subgroup analyses of video assisted thoracoscopic surgery (VATS) versus 
open thoracotomy 
Of the 23 participants in the NSCLC group, 12 (52%) underwent VATS and 11 (48%) 
underwent open thoracotomy. No differences were found in any outcome between those who 










mean ± SD 
Non-COPD (n=11) 
mean ± SD 
 
p value 
FEV1 (L) 1.63 ± 0.51 1.68 ± 0.50 0.21 
FEV1 (%pred) 62 ± 16 70 ± 16 0.16 
FEV1/FVC (%) 56 ± 11 70 ± 8 0.03 
VO2peak (L·min-1) 15 ± 3 15 ± 3 0.82 
6MWD (m) 501 ± 92 506 ± 47 0.53 
Isometric hangrip force (kg) 28 ± 6 29 ± 8 0.45 
Isometric quadriceps torque (Nm) 125 ± 67 131 ± 67 0.23 
PCS 45 ± 6 45 ± 4 0.76 
MCS 50 ± 7 52 ± 8 0.42 
HADS anxiety 4 ± 2 4 ± 3 0.89 
HADS depression 3 ± 2 3 ± 3 0.74 
Abbreviations: 6MWD – Six-minute walk distance; COPD – Chronic obstructive pulmonary disease; FEV1 – 
Forced expiratory volume in one second; FVC – Force vital capacity; MCS – Mental component score of the 
Medical outcomes study Short-Form 36 general health survey (SF-36); PCS – Physical component score of the 








VATS          
(n=12) 
mean ± SD 
Open thoracotomy 
(n=11) 
mean ± SD 
 
p value 
FEV1 (L) 1.68 ± 0.50 1.64 ± 0.39 0.25 
FEV1 (%pred) 68 ± 16 67 ± 18 0.54 
FEV1/FVC (%) 64 ± 11 63 ± 14 0.39 
VO2peak (L·min-1) 15 ± 3 14 ± 3 0.23 
6MWD (m) 515 ± 72 480 ± 78 0.10 
Isometric hangrip force (kg) 30 ± 6 27 ± 8 0.36 
Isometric quadriceps torque (Nm) 133 ± 71 124 ± 64 0.28 
PCS 45 ± 6 44 ± 5 0.66 
MCS 52 ± 7 50 ± 9 0.31 
HADS anxiety 5 ± 3 4 ± 2 0.58 
HADS depression 3 ± 3 3 ± 2 0.72 
Abbreviations: 6MWD – Six-minute walk distance; FEV1 – Forced expiratory volume in one second; FVC – 
Forced vital capacity; MCS – Mental component score of the Medical outcomes study Short-Form 36 general 
health survey (SF-36); PCS – Physical component score of the SF-36; SD – Standard deviation; VO2peak – Peak 




4.8 Subgroup analyses of people who attended the isometric quadriceps strength 
assessment 
Subgroup analyses comparing those who attended (12 participants) with those who did not 
attend (9 participants) the isometric quadriceps muscle torque assessment have been 
undertaken (Table A4). However no between-group differences in VO2peak, Wmax, 6MWD, 




Table A4:  Subgroup analyses comparing those who attended with those who did not attend 






mean ± SD 
Did not attend 
quadriceps 
assessment (n=9) 
mean ± SD 
 
p value 
FEV1 (L) 1.65 ± 0.54 1.69 ± 0.37 0.86 
FEV1 (%pred) 66 ± 18  69 ± 15 0.35 
FEV1/FVC (%) 63 ± 13 66 ± 15 0.49 
VO2peak (L·min-1) 15 ± 3 16 ± 2 0.52 
Wmax (W) 79 ± 24 70 ± 26 0.40 
6MWD (m) 503 ± 73 480 ± 80 0.20 
Isometric hangrip force (kg) 27 ± 6 29 ± 7 0.36 
PCS 45 ± 6 44 ± 5 0.72 
MCS 51 ± 8 51 ± 7 0.88 
HADS anxiety 3 ± 3 4 ± 3 0.33 
HADS depression 3 ± 2 3 ± 3 0.89 
Abbreviations: 6MWD – Six-minute walk distance; FEV1 – Forced expiratory volume in one second; FVC – 
Forced vital capacity; MCS – Mental component score of the Medical outcomes study Short-Form 36 general 
health survey (SF-36); PCS – Physical component score of the SF-36; SD – Standard deviation; VO2peak – Peak 





No correlation was demonstrated between 6MWD and isometric quadriceps torque. Further, 
data presented in the manuscript demonstrated that on completion of the 6MWT the average 
BORG score for leg fatigue of people in the NSCLC group was only 2±2 (Table 2). 
Therefore, it seems that quadriceps muscle force does not seem to play an important role in 
the reduction in 6MWD in people following lung resection for early stage NSCLC. 
Regarding maximal exercise capacity, isometric quadriceps torque correlated with both 
Wmax and VO2peak achieved during the CPET. These correlations are expected as, in contrast 
to walking, the quadriceps muscle is the main muscle group recruited during cycling. 
However, data reported in Table 2 shows that on completion of the CPET, compared with the 
healthy controls, those in the NSCLC group reported greater dyspnoea and had less 
ventilatory reserve (VEmax/MVV) and lower stroke volume (O2 pulse). Therefore, it seems 
that the impairment in exercise capacity in people following lung resection for early stage 
NSCLC may also result from cardiopulmonary / central factors rather than simply peripheral 
muscle issues.    
Caution is needed when interpreting the results of the subgroup comparisons due to the small 




[1] Cavalheri V, Tahirah F, Nonoyama M, Jenkins S, Hill K. Exercise training undertaken 
by people within 12 months of lung resection for non-small cell lung cancer. Cochrane 
Database Syst Rev 2013;7: CD009955. 
[2] ATS/ACCP Statement on cardiopulmonary exercise testing. Am J Respir Crit Care 
Med 2003;167: 211-277. 
[3] Pretto JJ, Braun GW, Guy PA. Using baseline respiratory function data to optimize 
cycle exercise test duration. Respirology 2001;6: 287-291. 
[4] Blackie SP, Fairbarn MS, McElvaney GN, Morrison NJ, Wilcox PG, Pardy RL. 
Prediction of maximal oxygen uptake and power during cycle ergometry in subjects 
older than 55 years of age. Am Rev Respir Dis 1989;139: 1424-1429. 
[5] Buchfuhrer MJ, Hansen JE, Robinson TE, Sue DY, Wasserman K, Whipp BJ. 
Optimizing the exercise protocol for cardiopulmonary assessment. J Appl Physiol 
Respir Environ Exerc Physiol 1983;55: 1558-1564. 
[6] Borg GA. Psychophysical bases of perceived exertion. Med Sci Sports Exerc 1982;14: 
377-381. 
[7] Nanas S, Sakellariou D, Kapsimalakou S, Dimopoulos S, Tassiou A, Tasoulis A, 
Anastasiou-Nana M, Vagiakis E, Roussos C. Heart rate recovery and oxygen kinetics 
after exercise in obstructive sleep apnea syndrome. Clin Cardiol 2010;33: 46-51. 
[8] Win T, Jackson A, Groves AM, Sharples LD, Charman SC, Laroche CM. Comparison 
of shuttle walk with measured peak oxygen consumption in patients with operable lung 
cancer. Thorax 2006;61: 57-60. 




[10] Jenkins S, Cecins N, Camarri B, Williams C, Thompson P, Eastwood P. Regression 
equations to predict 6-minute walk distance in middle-aged and elderly adults. 
Physiother Theory Pract 2009;25: 516-522. 
[11] McHorney CA, Ware JE, Jr., Lu JF, Sherbourne CD. The MOS 36-item Short-Form 
Health Survey (SF-36): III. Tests of data quality, scaling assumptions, and reliability 
across diverse patient groups. Med Care 1994;32: 40-66. 
[12] Stewart AL, Hays RD, Ware JE, Jr. The MOS short-form general health survey. 
Reliability and validity in a patient population. Med Care 1988;26: 724-735. 
[13] Prieto L, Alonso J, Ferrer M, Anto JM. Are results of the SF-36 health survey and the 
Nottingham Health Profile similar? A comparison in COPD patients. Quality of Life in 
COPD Study Group. J Clin Epidemiol 1997;50: 463-473. 
[14] Decramer M, Gosselink R, Troosters T, Verschueren M, Evers G. Muscle weakness is 
related to utilization of health care resources in COPD patients. Eur Respir J 1997;10: 
417-423. 
[15] Spruit MA, Sillen MJ, Groenen MT, Wouters EF, Franssen FM. New normative values 
for handgrip strength: results from the UK Biobank. J Am Med Dir Assoc 2013;14: 775 
e775-711. 
[16] Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, Crapo R, 
Enright P, van der Grinten CP, Gustafsson P, Jensen R, Johnson DC, MacIntyre N, 
McKay R, Navajas D, Pedersen OF, Pellegrino R, Viegi G, Wanger J, Force AET. 
Standardisation of spirometry. Eur Respir J 2005;26: 319-338. 
[17] Wanger J, Clausen JL, Coates A, Pedersen OF, Brusasco V, Burgos F, Casaburi R, 
Crapo R, Enright P, van der Grinten CP, Gustafsson P, Hankinson J, Jensen R, Johnson 
D, Macintyre N, McKay R, Miller MR, Navajas D, Pellegrino R, Viegi G. 
Standardisation of the measurement of lung volumes. Eur Respir J 2005;26: 511-522. 
20 
 
[18] Macintyre N, Crapo RO, Viegi G, Johnson DC, van der Grinten CP, Brusasco V, 
Burgos F, Casaburi R, Coates A, Enright P, Gustafsson P, Hankinson J, Jensen R, 
McKay R, Miller MR, Navajas D, Pedersen OF, Pellegrino R, Wanger J. 
Standardisation of the single-breath determination of carbon monoxide uptake in the 
lung. Eur Respir J 2005;26: 720-735. 
[19] American Thoracic Society/European Respiratory S. ATS/ERS Statement on 
respiratory muscle testing. Am J Respir Crit Care Med 2002;166: 518-624. 
[20] Hankinson JL, Odencrantz JR, Fedan KB. Spirometric reference values from a sample 
of the general U.S. population. Am J Respir Crit Care Med 1999;159: 179-187. 
[21] Crapo RO, Morris AH. Standardized single breath normal values for carbon monoxide 
diffusing capacity. Am Rev Respir Dis 1981;123: 185-189. 
[22] Black LF, Hyatt RE. Maximal respiratory pressures: normal values and relationship to 
age and sex. Am Rev Respir Dis 1969;99: 696-702. 
[23] Snaith RP. The Hospital Anxiety And Depression Scale. Health Qual Life Outcomes 
2003;1: 29. 
[24] Carroll BT, Kathol RG, Noyes R, Jr., Wald TG, Clamon GH. Screening for depression 
and anxiety in cancer patients using the Hospital Anxiety and Depression Scale. Gen 
Hosp Psychiatry 1993;15: 69-74. 
[25] Kramer JA. Use of the Hospital Anxiety and Depression Scale (HADS) in the 
assessment of depression in patients with inoperable lung cancer. Palliat Med 1999;13: 
353-354. 
[26] Gale CR, Allerhand M, Sayer AA, Cooper C, Dennison EM, Starr JM, Ben-Shlomo Y, 
Gallacher JE, Kuh D, Deary IJ, Team HAS. The structure of the Hospital Anxiety and 
Depression Scale in four cohorts of community-based, healthy older people: the 
HALCyon program. Int Psychogeriatr 2010;22: 559-571. 
21 
 
[27] Ofir D, Laveneziana P, Webb KA, Lam YM, O'Donnell DE. Mechanisms of dyspnea 
during cycle exercise in symptomatic patients with GOLD stage I chronic obstructive 
pulmonary disease. Am J Respir Crit Care Med 2008;177: 622-629. 
 
